Markets:

Overview

News

Currencies

International

Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

166.11 -0.72 (-0.43%)

Streaming Delayed Price Updated: 9:44 AM EDT, Aug 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy

AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To Know

August 12, 2025

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed...

Via StockStory

Topics Bonds Economy Stocks

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

RGEN Q2 Deep Dive: Chromatography and Filtration Drive Growth, Guidance Lifted Amid New Modalities Uncertainty

August 12, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q2 CY2025, with sales up 14.8% year on year to $182.4 million. The company’s full-year...

Via StockStory

1 Safe-and-Steady Stock on Our Buy List and 2 We Turn Down

August 07, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026 ↗

July 31, 2025

Repligen stock has been in a prolonged downtrend, and Adhishthana principles suggest more weakness ahead. Here's what investors should track...

Via Benzinga

Why Repligen (RGEN) Stock Is Up Today

July 29, 2025

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.8% in the morning session after the company reported strong second-quarter 2025 financial results and raised its...

Via StockStory

Topics Artificial Intelligence Lawsuit

Repligen Corp (NASDAQ:RGEN) Q2 2025 Earnings: Revenue Beat Offsets EPS Miss as Stock Rises in Pre-Market ↗

July 29, 2025

Repligen Corp's Q2 2025 earnings show revenue beat estimates at $182.4M, but EPS missed at $0.37. Stock rose 2.65% pre-market amid strong order growth.

Via Chartmill

Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic

July 29, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 14.8% year on year to $182.4 million. The...

Via StockStory

Repligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings

July 27, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting earnings this Tuesday before the bell. Here’s what to look for.

Via StockStory

Forecasting The Future: 6 Analyst Projections For Repligen ↗

July 22, 2025

Via Benzinga

Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know

July 18, 2025

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like...

Via StockStory

Topics Lawsuit

1 Healthcare Stock to Target This Week and 2 to Be Wary Of

July 03, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

What Analysts Are Saying About Repligen Stock ↗

June 24, 2025

Via Benzinga

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 16, 2025

Via Benzinga

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

June 10, 2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks

June 04, 2025

Let’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season.

Via StockStory

Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers

June 03, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and...

Via StockStory

3 of Wall Street’s Favorite Stocks in Hot Water

June 02, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know

May 12, 2025

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...

Via StockStory

Topics Government Stocks World Trade

1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

May 09, 2025

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,...

Via StockStory

Deep Dive Into Repligen Stock: Analyst Perspectives (8 Ratings) ↗

April 30, 2025

Via Benzinga

RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

April 30, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 10.4% year on year to $169.2 million. The company’s...

Via StockStory

Topics World Trade

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

April 29, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.4% year on year to $169.2 million. The...

Via StockStory

Topics World Trade

Repligen (RGEN) Q1 Earnings: What To Expect

April 28, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for.

Via StockStory

Topics World Trade

3 Healthcare Stocks That Concern Us

April 25, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...

Via StockStory

Topics Stocks

Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

April 10, 2025

Repligen trades at $120.32 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 10.5% while the S&P 500 is down 7.7%. This might have investors...

Via StockStory

Topics Stocks

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

March 26, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest...

Via StockStory

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

March 21, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.